Spots Global Cancer Trial Database for An Efficacy Study Of Ortataxel In Recurrent Glioblastoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Efficacy Study Of Ortataxel In Recurrent Glioblastoma
Official Title: Multicenter, Single Arm, Open-Label Phase II Trial On The Efficacy Of Ortataxel In Recurrent Glioblastoma
Study ID: NCT01989884
Conditions
Interventions
Study Description
Brief Summary: Italian Study On The Efficacy Of Ortataxel In Recurrent Glioblastoma
Detailed Description: In this phase II study, adult patients with histologically confirmed GBM in recurrence after surgery or biopsy, standard radiotherapy and chemotherapy with temozolomide were eligible. Patients included were treated with ortataxel 75 mg/m² i.v. every 3 weeks until disease progression. The primary objective of the study was to evaluate the efficacy of ortataxel in terms of progression free survival at six months after the enrolment (PFS-6).
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ospedale di Lecco, Lecco, , Italy
A.O. OSpedale Niguarda Ca' Granda, Milano, , Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, , Italy
Carlo Besta Neurological Foundation, Milan, , Italy
Fondazione "Salvatore Maugeri", Pavia, , Italy
IRCCS Fondazione "Casimiro Mondino", Pavia, , Italy
Istituti Fisioterapici Ospitalieri, Rome, , Italy
Contact Details
Name: Antonio Silvani, MD
Affiliation: Fondazione IRCCS Istituto Neurologico "Carlo Besta" di Milano
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
